Treatment of mixed connective tissue disease: A multicenter retrospective study.

Date publication

avril 2025

Journal

Journal of autoimmunity

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BONNOTTE Bernard

Tous les auteurs :
Chevalier K, Thoreau B, Michel M, Godeau B, Agard C, Papo T, Sacre K, Seror R, Mariette X, Cacoub P, Benhamou Y, Levesque H, Goujard C, Lambotte O, Bonnotte B, Samson M, Ackermann F, Schmidt J, Duhaut P, Jean-Emmanuel K, Hanslik T, Costedoat-Chalumeau N, Terrier B, Regent A, Dunogue B, Cohen P, Guern VL, Hachulla E, Chaigne B, Mouthon L

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40245724

Résumé

Mixed connective tissue disease (MCTD) is a rare systemic disorder that belongs to connective tissue diseases (CTD). Few studies are available on MCTD treatment.

Mots clés

Disease-modifying antirheumatic drugs, Glucocorticoids, Hydroxychloroquine, Immunosuppressant, Interstitial lung disease, Mixed connective tissue disease, Pulmonary arterial hypertension

Référence

J Autoimmun. 2025 04 16;153:103420